To the Editor We read with great interest the study from Glass et al1 exploring the conundrum of continuation vs cessation of antiseizure medication (ASM) after acute symptomatic neonatal seizures. The study represents, to our knowledge, the largest and most systematic on the topic and is an important step toward an evidence-based approach to ASM use in this vulnerable population.